Psychoaktive Nachrichten (1) - Cannabis - Kratom - CBD // 25.10.16

Kratom and cannabis policy in the United States encounter significant public resistance. Grassroots advocacy successfully prompted the Drug Enforcement Administration to delay its decision on classifying Kratom as an illegal Schedule 1 substance, reflecting a rare instance of government reversal in response to public pressure. This botanical is valued by many for its potential in managing pain, depression, and opiate withdrawal. Cannabis remains a focus of intense public interest, particularly in California, where legalization looms. Corporate influence from industry giants like Bayer and Monsanto looms over the cannabis market, raising concerns about the potential for industrialization to undermine the livelihoods of small scale growers. Meanwhile, CBD regulations in Germany and the UK have shifted abruptly, resulting in a new mandate that restricts access to CBD solely through a prescription-only model, complicating access for those utilizing it for health.